First Patient in Cook’s Zilver PTX Drug Stent Chinese Study

A first patient has been enrolled in Cook Medical’s clinical study in China of its Zilver® PTX® Drug Eluting Peripheral Stent. The case was performed by one of the study’s principal investigators, Prof. Peng Liu, M.D., at the China-Japan Friendship Hospital in Beijing.

Background

Cook’s Zilver PTX Drug Eluting Peripheral Stent is indicated for treatment of symptomatic vascular disease of the above-the-knee femoropopliteal arteries having a reference vessel diameter from 4 mm to 9 mm. The company says that to date, the device has been studied clinically in more than 2,200 patients worldwide, being already approved for commercial sale in the United States, Japan, Europe, Canada, Australia, Brazil, India and other markets

The study, the first of its kind in China, is being conducted at up to 20 clinical sites and will enroll 175 patients with one-year follow-up. It will evaluate the performance of the Zilver PTX stent to treat peripheral artery disease (PAD) in the superficial femoral artery. Chinese patient outcome data will be compared to patient results shown in Cook’s global randomized clinical study of the device. The study is a pre-market requirement of the China Food and Drug Administration (CFDA). Data collected will be submitted to CFDA in support of commercial registration of Zilver PTX in China.

Physician comments

“It’s great to have enrolled the first case of Zilver PTX China clinical trial by our center,” said Prof. Liu. “The product represents the latest drug technology in the peripheral vascular system. We are looking forward to bringing this new technology to Chinese patients to overcome the troublesome restenosis problem.”

Company comments

“Based on the evidence to date1, we’re convinced drug elution is the future of treating PAD. This milestone moves Cook one step closer to bringing this remarkable technology to Chinese physicians and the patients they treat,” said Mark Breedlove, vice president and global leader of Cook’s Peripheral Intervention clinical division. “We look forward to concluding this study quickly and making a timely submission to CFDA.”

Source: Cook Medical, Business Wire

Share your thoughts

Your email address will not be published. Required fields are marked *